22 results on '"Halasz, K."'
Search Results
2. B Cell-Activating Factor Enhances Interleukin-6 and Interleukin-10 Production by ODN-Activated Human B Cells
- Author
-
Yehudai, D., Snir, A., Peri, R., Halasz, K., Haj, T., Odeh, M., and Kessel, A.
- Published
- 2012
- Full Text
- View/download PDF
3. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis
- Author
-
Vadasz, Z. Goldeberg, Y. Halasz, K. Rosner, I. Valesini, G. Conti, F. Perricone, C. Sthoeger, Z. Bezalel, S.R. Tzioufas, A.G. Levin, N.A. Shoenfeld, Y. Toubi, E.
- Subjects
skin and connective tissue diseases - Abstract
Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated. Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed. Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies. Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE. © 2015 .
- Published
- 2016
4. Photo-induced changes and contact relaxation of the surface AC-conductivity of the paper prepared from poly(ethyleneimine)–TiO2–anthocyanin modified cellulose fibers
- Author
-
Csóka, L., primary, Dudić, D., additional, Petronijević, I., additional, Rozsa, C., additional, Halasz, K., additional, and Djoković, V., additional
- Published
- 2014
- Full Text
- View/download PDF
5. AB0195 Semaphorin 3A as A Possible Immunoregulator in Systemic Sclerosis
- Author
-
Rimar, D., primary, Rosner, I., additional, Slobodin, G., additional, Boulman, N., additional, Rozenbaum, M., additional, Halasz, K., additional, Haj, T., additional, Jiries, N., additional, Kaly, L., additional, and Vadasz, Z., additional
- Published
- 2014
- Full Text
- View/download PDF
6. AN EFFICIENT MICROPROPAGATION SYSTEM: 3R BIOREACTOR
- Author
-
Mészaros, A., primary, Domokos-Szabolcsy, E., additional, Halasz, K., additional, Kalai, K., additional, and Fari, M.G., additional
- Published
- 2006
- Full Text
- View/download PDF
7. Nanoparticle drug delivery characterization for fluticasone propionate and in vitro testing 1 .
- Author
-
Sutariya V, Kelly SJ, Weigel RG, Tur J, Halasz K, Sharma NS, and Tipparaju SM
- Subjects
- Animals, Cell Line, Drug Liberation, Hydrogen-Ion Concentration, L-Lactate Dehydrogenase metabolism, Mice, Particle Size, Drug Carriers chemistry, Fluticasone chemistry, Fluticasone pharmacology, Nanoparticles chemistry
- Abstract
Glucocorticoids, such as fluticasone propionate (FP), are used for the treatment of inflammation and alleviation of nasal symptoms and allergies, and as an antipruritic. However, both short- and long-term therapeutic use of glucocorticoids can lead to muscle weakness and atrophy. In the present study, we evaluated the feasibility of the nanodelivery of FP with poly(dl-lactide-co-glycolide) (PLGA) and tested in vitro function. FP-loaded PLGA nanoparticles were prepared via nanoprecipitation and morphological characteristics were studied via scanning electron microscopy. FP-loaded nanoparticles demonstrated an encapsulation efficiency of 68.6% ± 0.5% with a drug loading capacity of 4.6% ± 0.04%, were 128.8 ± 0.6 nm in diameter with a polydispersity index of 0.07 ± 0.008, and displayed a zeta potential of -19.4 ± 0.7. A sustained in vitro drug release pattern was observed for up to 7 days. The use of fluticasone nanoparticle decreased lipopolysaccharide (LPS)-induced lactate dehydrogenase release compared with LPS alone in C2C12 treated cells. FP also decreased expression of LPS-induced inflammatory genes in C2C12 treated cells as compared with LPS alone. Taken together, the present study demonstrates in vitro feasibility of PLGA-FP nanoparticle delivery to the skeletal muscle cells, which may be beneficial for treating inflammation.
- Published
- 2019
- Full Text
- View/download PDF
8. Micro/Nanoparticle Delivery Systems for Ocular Diseases.
- Author
-
Halasz K, Kelly SJ, Iqbal MT, Pathak Y, and Sutariya V
- Subjects
- Animals, Drug Carriers chemistry, Humans, Drug Delivery Systems, Dry Eye Syndromes drug therapy, Glaucoma drug therapy, Nanoparticles chemistry
- Abstract
Micro- (MPs) and nanoparticles (NPs) have been recently studied for their application in ophthalmic drug delivery. These drug delivery systems are able to circumvent the ocular barriers that currently limit the efficacy of conventional treatments, as well as provide a more sustained release of drug, reducing the frequency of administration and increasing patient compliance. This review summarizes the recent trends in ophthalmic research from conventional treatment to the utilization of MPs and NPs as drug carriers.
- Published
- 2019
- Full Text
- View/download PDF
9. Nanodelivery of doxorubicin for age-related macular degeneration.
- Author
-
Kelly SJ, Halasz K, Smalling R, and Sutariya V
- Subjects
- Cell Line, Chemical Precipitation, Doxorubicin pharmacokinetics, Drug Compounding methods, Drug Liberation, Drug Stability, Emulsions, Epithelial Cells, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Macular Degeneration pathology, Nanoparticles chemistry, Particle Size, Polymers chemistry, Retinal Pigment Epithelium cytology, Vascular Endothelial Growth Factor A metabolism, Doxorubicin administration & dosage, Drug Carriers chemistry, Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors, Macular Degeneration drug therapy
- Abstract
Objective: Polymeric nanoparticles (NPs) containing doxorubicin (DOX) were prepared for the inhibition of hypoxia-induced factor 1α (HIF-1α)., Significance: HIF-1α is responsible for the upregulation of several angiogenic factors, including vascular endothelial growth factor (VEGF). DOX inhibits HIF-1α but is highly toxic. By encapsulating DOX in NPs, drug delivery will be sustained and toxicity will be reduced without limiting efficacy., Methods: DOX NPs were prepared using both polylactic coglycolic acid (PLGA) and chitosan. PLGA NPs were prepared via nanoprecipitation (NPC) and single and double emulsion diffusion (SE; DE). Chitosan NPs were formulated using ionic gelation (IG), and complex coacervation (CC). Size, polydispersity index (PDI), and zeta potential (ZP) were determined via dynamic light scattering (DLS) (n = 3). The encapsulation efficiency (EE), drug loading capacity (DLC) (n = 3) and in vitro drug release profiles (IVR) at 37 °C (n = 4) were analyzed via spectroscopy at 480 nm (λ
max ). The cytotoxicity of each formulation as well as free DOX solution in ARPE-19 cells was determined via MTT assay after 24 h (n = 3). HIF-1α and VEGF inhibition in ARPE-19 cells were measured via ELISA (n = 3)., Results: The results were consistent with the hypothesis; the NP formulations decreased HIF-1α and VEGF-A expression in ARPE-19 cells with reduced cytotoxicity. SE, DE, and CC demonstrated low ZP as well as the most rapid drug release of the tested formulations. FTIR confirmed the presence of DOX on the SE NP surface, indicating instability., Conclusions: SE, DE, and CC destabilized. NPC was the most efficient formulation for the nanodelivery of DOX for AMD.- Published
- 2019
- Full Text
- View/download PDF
10. Utilization of Apatinib-Loaded Nanoparticles for the Treatment of Ocular Neovascularization.
- Author
-
Halasz K, Kelly SJ, Iqbal MT, Pathak Y, and Sutariya V
- Subjects
- Antineoplastic Agents chemistry, Cell Line, Drug Carriers chemistry, Eye Diseases drug therapy, Humans, Nanoparticles chemistry, Neovascularization, Pathologic drug therapy, Protein Kinase Inhibitors chemistry, Pyridines chemistry, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor Receptor-2 metabolism, Antineoplastic Agents administration & dosage, Drug Carriers administration & dosage, Nanoparticles administration & dosage, Protein Kinase Inhibitors administration & dosage, Pyridines administration & dosage
- Abstract
Background: The current treatment of ocular neovascularization requires frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents that cause severe side effects., Objective: The purpose of this study is to prepare and characterize a novel nanoscale delivery system of apatinib for ocular neovascularization., Methods: The optimized formulation showed a particle size of 135.04 nm, polydispersity index (PDI) of 0.28 ± 0.07, encapsulation efficiency (EE) of 65.92%, zeta potential (ZP) of -23.70 ± 8.69 mV, and pH of 6.49 ± 0.20. In vitro release was carried out to demonstrate a 3.13-fold increase in the sustainability of apatinib-loaded nanoparticles versus free apatinib solution., Result: Cell viability and VEGFA and VEGFR2 expression were analyzed in animal retinal pigment epithelial (ARPE-19) cells., Conclusion: The results confirmed the hypothesis that apatinib nanoparticles decreased toxicity (1.36 ± 0.74 fold) and efficient VEGF inhibition (3.51 ± 0.02 fold) via VEGFR2 mediation., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF
11. Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro Model: A Preliminary Report.
- Author
-
Kelly SJ, Hirani A, Shahidadpury V, Solanki A, Halasz K, Varghese Gupta S, Madow B, and Sutariya V
- Abstract
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the United States, affecting approximately 11 million patients. AMD is caused primarily by an upregulation of vascular endothelial growth factor (VEGF). In recent years, aflibercept injections have been used to combat VEGF. However, this treatment requires frequent intravitreal injections, leading to low patient compliance and several adverse side effects including scarring, increased intraocular pressure, and retinal detachment. Polymeric nanoparticles have demonstrated the ability to deliver a sustained release of drug, thereby reducing the necessary injection frequency. Aflibercept (AFL) was encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) via double emulsion diffusion. Scanning electron microscopy showed the NPs were spherical and dynamic light scattering demonstrated that they were uniformly distributed (PDI < 1). The encapsulation efficiency and drug loading were 75.76% and 7.76% respectively. In vitro release studies showed a sustained release of drug; 75% of drug was released by the NPs in seven days compared to the full payload released in 24 h by the AFL solution. Future ocular in vivo studies are needed to confirm the biological effects of the NPs. Preliminary studies of the proposed aflibercept NPs demonstrated high encapsulation efficiency, a sustained drug release profile, and ideal physical characteristics for AMD treatment. This drug delivery system is an excellent candidate for further characterization using an ocular neovascularization in vivo model.
- Published
- 2018
- Full Text
- View/download PDF
12. Nanodrug delivery platform for glucocorticoid use in skeletal muscle injury.
- Author
-
Sutariya V, Tur J, Kelly S, Halasz K, Chapalamadugu KC, Nimbalkar R, Pathak YV, Weigel R, Daviau T, Webb T, Cacace J, Brotto M, and Tipparaju SM
- Subjects
- Animals, Biological Availability, Cell Line, Cell Survival drug effects, Dexamethasone pharmacology, Dexamethasone therapeutic use, Drug Liberation, Glucocorticoids therapeutic use, Lactic Acid chemistry, Mice, Microscopy, Electron, Transmission, Muscle, Skeletal cytology, Muscle, Skeletal drug effects, Muscle, Skeletal injuries, Myoblasts drug effects, Nanoparticles ultrastructure, Polyglycolic Acid chemistry, Polylactic Acid-Polyglycolic Acid Copolymer, Rats, Drug Compounding methods, Glucocorticoids pharmacology, Myositis drug therapy, Nanoparticles chemistry, Wound Healing drug effects
- Abstract
Glucocorticoids are utilized for their anti-inflammatory properties in the skeletal muscle and arthritis. However, the major drawback of use of glucocorticoids is that it leads to senescence and toxicity. Therefore, based on the idea that decreasing particle size allows for increased surface area and bioavailability of the drug, in the present study, we hypothesized that nanodelivery of dexamethasone will offer increased efficacy and decreased toxicity. The dexamethasone-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared using nanoprecipitation method. The morphological characteristics of the nanoparticles were studied under scanning electron microscope. The particle size of nanoparticles was 217.5 ± 19.99 nm with polydispersity index of 0.14 ± 0.07. The nanoparticles encapsulation efficiency was 34.57% ± 1.99% with in vitro drug release profile exhibiting a sustained release pattern over 10 days. We identified improved skeletal muscle myoblast performance with improved closure of the wound along with increased cell viability at 10 nmol/L nano-dexamethasone-PLGA. However, dexamethasone solution (1 μmol/L) was injurious to cells because the migration efficiency was decreased. In addition, the use of dexamethasone nanoparticles decreased lipopolysaccharide-induced lactate dehydrogenase release compared with dexamethasone solution. Taken together, the present study clearly demonstrates that delivery of PLGA-dexamethasone nanoparticles to the skeletal muscle cells is beneficial for treating inflammation and skeletal muscle function.
- Published
- 2018
- Full Text
- View/download PDF
13. Semaphorin 3A: Is a key player in the pathogenesis of asthma.
- Author
-
Cozacov R, Halasz K, Haj T, and Vadasz Z
- Subjects
- Adult, Asthma metabolism, Case-Control Studies, Coculture Techniques, Culture Media, Conditioned, Female, Forkhead Transcription Factors drug effects, Forkhead Transcription Factors metabolism, Humans, Male, Middle Aged, Recombinant Proteins, Semaphorin-3A pharmacology, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory metabolism, Asthma immunology, Semaphorin-3A metabolism, T-Lymphocytes, Regulatory immunology
- Abstract
Immune semaphorins are key players in regulating immune mediated inflammation. Semaphorin3A (sema3A) a secreted and membrane bound member of this family, is well reported for its properties in maintaining self-tolerance. Semaphorin3A was recognized to be a marker for T-regulatory cells (Tregs), and as such is a useful tool for assessing the status of these cells in preventing immune mediated diseases. This study was designed aiming to evaluate how sema3A is possibly involved in bronchial asthma. Here, we found sema3A serum levels and the expression of sema3A on Tregs significantly lower in patients with moderate to severe asthma when compared to healthy individuals. Co-culture of condition medium with 2mcg/ml of recombinant human sema3A with CD4+ T cells, increased the expression of FoxP3 in Tregs, suggesting sema3A a potent immune-regulator of inflammation including that of asthma. Further in-vivo studies will better establish the beneficial effect of sema3A in regulating inflammation in asthma., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
14. Semaphorin 3A, a potential immune regulator in familial Mediterranean fever.
- Author
-
Rimar D, Rosner I, Slobodin G, Rozenbaum M, Halasz K, Jiries N, Kaly L, Boulman N, and Vadasz Z
- Subjects
- Adult, B-Lymphocytes, Regulatory immunology, Biomarkers blood, Case-Control Studies, Disease Progression, Down-Regulation, Familial Mediterranean Fever diagnosis, Familial Mediterranean Fever drug therapy, Familial Mediterranean Fever immunology, Female, Humans, Male, Middle Aged, Remission Induction, Semaphorin-3A immunology, T-Lymphocytes, Regulatory immunology, B-Lymphocytes, Regulatory metabolism, Familial Mediterranean Fever blood, Semaphorin-3A blood, T-Lymphocytes, Regulatory metabolism
- Abstract
Objectives: Semaphorin 3A (sema3A) plays a regulatory role in immune responses with effects on both T and B regulatory cells. Familial Mediterranean fever (FMF) is an autoinflammatory disease, yet a possible role for regulatory T and B cells has been described., Methods: 17 FMF patients during attack and then in remission, 8 FMF patients with smoldering disease and 12 healthy controls were enrolled. Sema3A in serum and its expression on regulatory T and B cells was evaluated. Clinical parameters of FMF patients were assessed., Results: Semaphorin 3A serum level was lower in FMF patients during attack, smoldering disease or remission than healthy controls, (242.3±9.8 ng/ ml vs. 258.9±11.5 ng/ml vs. 232.5±22.7 ng/ml vs. 323.3±160.2 ng/ml, respectively p<0.05). This decrease was specifically noted on regulatory B and T cells in FMF patients during attack and in smoldering disease and normalized in remission., Conclusions: Sema3A expression on T and B regulatory lymphocytes is low in FMF patients during attack and in smoldering disease compared to the expression in remission and healthy controls. These results are in line with previous descriptions suggesting a possible role of regulatory T cells in termination of FMF attacks. Further studies are needed to verify these preliminary findings.
- Published
- 2016
15. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis.
- Author
-
Vadasz Z, Goldeberg Y, Halasz K, Rosner I, Valesini G, Conti F, Perricone C, Sthoeger Z, Bezalel SR, Tzioufas AG, Levin NA, Shoenfeld Y, and Toubi E
- Subjects
- Adolescent, Adult, Antibodies, Antinuclear blood, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid immunology, B-Lymphocytes immunology, Biomarkers blood, Female, Humans, Lupus Erythematosus, Systemic blood, Male, Middle Aged, Semaphorins blood, Severity of Illness Index, Young Adult, Antigens, CD blood, Antigens, Differentiation, B-Lymphocyte blood, Lupus Erythematosus, Systemic immunology
- Abstract
Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated., Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed., Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies., Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
16. Semaphorin 3A: an immunoregulator in systemic sclerosis.
- Author
-
Rimar D, Nov Y, Rosner I, Slobodin G, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Boulman N, and Vadasz Z
- Subjects
- Adult, Biomarkers blood, Female, Humans, Male, Middle Aged, Scleroderma, Systemic blood, Semaphorin-3A blood, Scleroderma, Systemic metabolism, Semaphorin-3A metabolism, T-Lymphocytes, Regulatory metabolism
- Abstract
Abstarct: Semaphorin 3A (sema3A) plays a regulatory role in immune responses, mainly affecting the activation of regulatory T cells. It has been found to correlate with disease activity in rheumatoid arthritis and systemic lupus erythematosus (SLE). To investigate the expression of sema3A in patients with systemic sclerosis (SSc) compared to healthy controls and SLE disease controls and to correlate it with clinical characteristics, 27 SSc patients, 42 SLE patients and 28 healthy controls were enrolled. Serum level of sema3A was measured by ELISA, and expression of sema3A on regulatory T cells was evaluated by FACS analysis. SSc patients were evaluated for demographics, clinical manifestations, routine laboratory results, nailfold videocapillaroscopy, pulmonary function tests, echocardiograms, modified Rodnan skin score, and disease activity and severity scores. Serum levels of semaphorin 3A were lower in SSc compared to healthy controls 14.38 ± 5.7 versus 27.14 ± 8.4 ng/ml, p < 0.0001 and similar to SLE 15.7 ± 4.3 ng/ml. The expression of semaphorin 3A on regulatory T cells was also lower in SSc compared to healthy controls 61.7 ± 15.7 versus 88.7 ± 3. 7 % (p < 0.0001). Semaphorin 3A serum level inversely correlated with the duration of disease: r = -0.4, p = 0.036 and with low C4 level r = 0.66, p = 0.026. SCL-70 antibody positivity was associated with a lower semaphorin 3A level (difference in mean of 3.44, p = 0.06). Sema3A expression is low in SSc serum and more specifically on regulatory T cells. This may help explain the reduced activation of regulatory T cells in SSc.
- Published
- 2015
- Full Text
- View/download PDF
17. The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs).
- Author
-
Vadasz Z, Rainis T, Nakhleh A, Haj T, Bejar J, Halasz K, and Toubi E
- Subjects
- Adult, Aged, Case-Control Studies, Colitis, Ulcerative immunology, Colitis, Ulcerative metabolism, Crohn Disease immunology, Crohn Disease metabolism, Female, Humans, Immunohistochemistry, Male, Middle Aged, Semaphorin-3A blood, Semaphorins blood, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Young Adult, Colitis, Ulcerative pathology, Crohn Disease pathology, Semaphorin-3A analysis, Semaphorins analysis
- Abstract
Background and Aims: Immune semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. We aim to assess the possible involvement of semaphorin3A (sema3A) and 4A (sema4A) in peripheral immune responses and bowel tissue inflammation of patients suffering from Crohn's disease (CD) and ulcerative colitis (UC)., Patients and Methods: Twenty-seven CD patients and 10 UC patients were studied and compared to 10 patients followed for acute diverticulitis (disease control) and 12 healthy individuals. All were evaluated for sema3A expression on T regulatory cells (Tregs), serum levels of sema3A and sema4A, and tissue expression of sema3A and sema4A in bowel biopsies., Results: The percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ± 14.49%) and active UC (49.8% ± 16.45%) was significantly lower when compared to that of healthy controls (88.7% ± 3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69 ± 1 .48 ng\ml for CD, 5.26 ± 1.23 ng/ml for UC patients vs 9.74 ± 2.73 ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals., Conclusions: Altered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.
- Published
- 2015
- Full Text
- View/download PDF
18. Interferon-gamma-release assay prevents unnecessary tuberculosis therapy.
- Author
-
Schichter-Konfino V, Halasz K, Grushko G, Snir A, Haj T, Vadasz Z, Kessel A, Potasman I, and Toubi E
- Subjects
- Emigrants and Immigrants statistics & numerical data, False Positive Reactions, Female, Humans, Incidence, Israel epidemiology, Male, Mass Screening methods, Tuberculin Test methods, Antitubercular Agents therapeutic use, Drug Therapy statistics & numerical data, Interferon-gamma Release Tests methods, Interferon-gamma Release Tests statistics & numerical data, Tuberculosis diagnosis, Tuberculosis epidemiology, Tuberculosis therapy, Unnecessary Procedures
- Abstract
Background: The mass influx of immigrants from tuberculosis-endemic countries into Israel was followed by a considerable increase in the incidence of tuberculosis (TB). All contacts of active TB patients are obliged to be screened by tuberculin skin tests (TST) and, if found positive, prophylactic treatment is considered., Objectives: To assess the utility of interferon-gamma (IFNγ)-release assay with a prolonged follow-up in preventing unnecessary anti-TB therapy in individuals with suspected false positive results., Methods: Between 2008 and 2012 the QuantiFERON TB gold-in-tube test (QFT-G) was performed in 278 sequential individuals who were mostly TST-positive and/or were in contact with an active TB patient. In all, whole blood was examined by the IFNγ-release assay. We correlated the TST diameter with the QFT-G assay and followed those patients with a negative assay., Results: The QFT-G test was positive in only 72 (42%) of all 171 TST-positive individuals. There was no correlation between the diameter of TST and QFT-G positivity. Follow-up over 5 years was available in 128 (62%) of all QFT-G-negative individuals. All remained well and none developed active TB., Conclusions: A negative QFT-G test may obviate the need for anti-TB therapy in more than half of those with a positive TST.
- Published
- 2015
19. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis.
- Author
-
Rimar D, Rosner I, Nov Y, Slobodin G, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Boulman N, Daood R, and Vadasz Z
- Subjects
- Adult, Biomarkers blood, Female, Fibrosis blood, Fibrosis etiology, Humans, Lung physiopathology, Male, Middle Aged, Respiratory Function Tests, Scleroderma, Systemic blood, Scleroderma, Systemic physiopathology, Skin Diseases blood, Skin Diseases etiology, Fibrosis diagnosis, Protein-Lysine 6-Oxidase blood, Scleroderma, Systemic complications, Skin Diseases diagnosis
- Abstract
Objective: Fibrosis is a major cause of morbidity and mortality in systemic sclerosis (SSc). Levels of lysyl oxidase (LOX), an extracellular enzyme that stabilizes collagen fibrils, have been found to be elevated in the skin of SSc patients, but have not been evaluated in the serum or correlated with the clinical parameters. We undertook this study to evaluate serum LOX levels in SSc patients and to correlate these levels with clinical parameters of SSc., Methods: SSc patients were evaluated for demographic features, clinical manifestations, routine laboratory tests, serum autoantibodies, serum LOX concentrations, and nailfold capillaroscopy patterns. They underwent pulmonary function testing, echocardiography, and high-resolution computed tomography scans of the lung, assessment of skin fibrosis by the modified Rodnan skin thickness score (MRSS), and assessment of disease severity and activity by the Medsger severity scale and the Valentini activity index., Results: Twenty-six SSc patients were evaluated and compared with 25 healthy controls and with 9 disease control patients with primary myelofibrosis. Almost 62% of the SSc patients (16 of 26) had limited cutaneous SSc (lcSSc), while 38% had diffuse cutaneous SSc (dcSSc) (10 of 26); 31% of the patients (8 of 26) had lung involvement. The LOX concentration in SSc patients was higher than that in healthy controls and similar to that in disease controls (P < 0.0001), and it was significantly higher in patients with dcSSc than in those with lcSSc (P = 0.006). The LOX concentration correlated with the MRSS in patients without lung fibrosis., Conclusion: This study is the first to demonstrate high serum LOX levels in SSc patients that correlate specifically with skin fibrosis. These correlations suggest that LOX levels may serve as a novel biomarker of fibrosis. Future studies are warranted to determine whether LOX is a potential therapeutic target in SSc., (Copyright © 2014 by the American College of Rheumatology.)
- Published
- 2014
- Full Text
- View/download PDF
20. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus.
- Author
-
Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, Kessel A, Kessler O, Neufeld G, and Toubi E
- Subjects
- B-Lymphocytes immunology, B-Lymphocytes metabolism, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Biomarkers blood, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic immunology, Semaphorin-3A blood
- Abstract
Introduction: Semaphorin 3A (sema3A) and neuropilin-1 (NP-1) play a regulatory role in immune responses and have a demonstrated effect on the course of collagen induced arthritis. This study was undertaken to evaluate the role of sema3A and NP-1 in the pathogenesis of systemic lupus erythematosus (SLE) and the specific effect of sema3A on the auto-reactive properties of B cells in SLE patients., Methods: Thirty two SLE and 24 rheumatoid arthritis (RA) patients were assessed and compared with 40 normal individuals. Sema3A serum levels were measured and correlated with SLE disease activity. The in vitro effect of sema3A in reducing Toll-like receptor 9 (TLR-9) expression in B cells of SLE patients was evaluated., Results: Sema3A serum levels in SLE patients were found to be significantly lower than in RA patients (55.04 ± 16.30 ng/ml versus 65.54 ± 14.82 ng/ml, P = 0.018) and lower yet than in normal individuals (55.04 ± 16.30 ng/ml versus 74.41 ± 17.60 ng/ml, P < 0.0001). Altered serum sema3A levels were found to be in inverse correlation with SLE disease activity, mainly with renal damage. The expression of both sema3A and NP-1 on B cells from SLE patients was significantly different in comparison with normal healthy individuals. Finally, when sema3A was co-cultured with cytosine-phosphodiester-guanine oligodeoxynucleotides (CpG-ODN)-stimulated B cells of SLE patients, their TLR-9 expression was significantly reduced, by almost 50% (P = 0.001)., Conclusions: This is the first study in which a reduced serum level of sema3A was found in association with SLE disease activity. It also raises the possibility that sema3A may have a regulatory function in SLE.
- Published
- 2012
- Full Text
- View/download PDF
21. Changes in immunomodulatory constituents of human milk in response to active infection in the nursing infant.
- Author
-
Riskin A, Almog M, Peri R, Halasz K, Srugo I, and Kessel A
- Subjects
- Adult, Case-Control Studies, Chi-Square Distribution, Female, Humans, Immunoglobulin A, Secretory metabolism, Infant, Infant, Newborn, Interleukin-10 metabolism, Israel, Lactoferrin metabolism, Leukocyte Common Antigens metabolism, Leukocyte Count, Macrophages immunology, Male, Milk, Human cytology, Tumor Necrosis Factor-alpha metabolism, Breast Feeding, Communicable Diseases immunology, Leukocytes immunology, Milk, Human immunology
- Abstract
Introduction: To investigate whether immunologic factors in breast milk change in response to nursing infants' infection., Results: Total CD45 leukocyte count dropped from 5,655 (median and interquartile range: 1,911; 16,871) in the acute phase to 2,122 (672; 6,819) cells/ml milk after recovery with macrophage count decreasing from 1,220 (236; 3,973) to 300 (122; 945) cells/ml. Tumor necrosis factor-α (TNFα) levels decreased from 3.66 ± 1.68 to 2.91 ± 1.51 pg/ml. The decrease in lactoferrin levels was of borderline statistical significance. Such differences were not recorded in samples of the controls. Interleukin-10 levels decreased in the sick infants' breast milk after recovery, but also in the healthy controls, requiring further investigation. Secretory immunoglobulin A levels did not change significantly in the study or control group., Discussion: During active infection in nursing infants, the total number of white blood cells, specifically the number of macrophages, and TNFα levels increase in their mothers' breast milk. These results may support the dynamic nature of the immune defense provided by breastfeeding sick infants., Methods: Breast milk from mothers of 31 infants, up to 3 months of age, who were hospitalized with fever, was sampled during active illness and recovery. Milk from mothers of 20 healthy infants served as controls.
- Published
- 2012
- Full Text
- View/download PDF
22. Antibody clustering helps refine lupus prognosis.
- Author
-
Kessel A, Rosner I, Halasz K, Grushko G, Shoenfeld Y, Paran D, and Toubi E
- Subjects
- Adolescent, Adult, Biomarkers blood, C-Reactive Protein metabolism, Female, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Lupus Erythematosus, Systemic blood, Male, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Rheumatoid Factor blood, Young Adult, Antibodies, Antinuclear blood, DNA immunology, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic immunology, Severity of Illness Index
- Abstract
Objective: Our aim was to investigate a possible association between patterns of anti-dsDNA antibody isotypes (IgG, IgM, and IgA), rheumatoid factor (RF) isotypes (IgG, IgM, IgA), and IgG anti-C reactive protein (CRP) and systemic lupus erythematosus (SLE) disease activity (SLEDAI)., Methods: Our study group included 98 patients, 86 women and 12 men, with a mean SLEDAI score of 7.9 +/- 4.1. We divided the patients into 4 groups by the serum anti-dsDNA antibody isotype intensity level., Results: We found that patients in group 1 (IgG > IgM, 42 patients) had a statistically significantly higher SLEDAI score than group 2 (IgG < IgM, 13 patients) (10.57 +/- 4.62 versus 5.6 +/- 4, P = 0.0012), group 3 (IgG = IgM, 8 patients) (10.57 +/- 4.62 versus 6.2 +/- 1.98, P = 0.04), and group 4 (none, 35 patients) (10.57 +/- 4.62 versus 6 +/- 1.5, P = 0.0001). SLE patients with IgG RF or IgM RF isotype present had a significantly higher SLEDAI score compared with those without IgG RF or IgM RF (10.57 +/- 4.8 versus 7.6 +/- 4.1, P = 0.03, 10.6 +/- 5 versus 7.6 +/- 3.9, P = 0.046). The presence of IgA RF isotype was not associated with a higher SLEDAI score. IgG anti-CRP did not correlate differentially with SLEDAI scores., Conclusions: A combination of high-titer IgG anti-dsDNA with a positive RF of IgM isotype may serve as a marker for more active SLE.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.